Enzyme Linked Immunosorbent Assay (ELISA) News and Research

RSS

Can cancer patients receive urgent care without risk of COVID-19?

A new study describes how a successful application of mitigation techniques to prevent COVID-19 transmission to cancer patients admitted to or attending a healthcare facility might look.

21 Jan 2021

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

In an exciting, state-of-the-art study currently available on the medRxiv* preprint server, US researchers created a multi-coronavirus protein microarray containing full-length proteins, peptide libraries, and overlapping protein fragments from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as four other human coronaviruses.

19 Jan 2021

Lower CD4 T cell reactivity to seasonal coronaviruses found in healthcare workers with COVID-19

A new study by US-based researchers describes the results of a study on the immune response among healthcare workers, in particular, their T cell responses predating the pandemic.

19 Jan 2021

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

An interesting new preprint research paper that was posted on the bioRxiv* server recently describes the use of rigid monoclonal antibodies (mAbs) in contrast to flexible mAbs, and how this affects the binding of multiple mAbs to the same antigen.

17 Jan 2021

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

A recent study, currently available on the medRxiv* preprint server, is among the first to reveal the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in colostrum and to demonstrate elevated cytokine levels in colostrum from women exposed to the virus.

7 Jan 2021

Higher BMI linked to increased risk of SARS-CoV-2 infection

Researchers at the University of Miami Miller School of Medicine, USA, revealed that the spike-specific immunoglobulin G antibodies in obese people are negatively associated with body mass index (BMI) and serum levels of proinflammatory and metabolic markers of pulmonary inflammation.

24 Dec 2020

EKF launches high performance quantitative COVID-SeroKlir antibody test kit

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.

From EKF Diagnostics 10 Dec 2020

Study suggests vast majority of Seattle population remains susceptible to COVID-19

Researchers in the United States have conducted a study suggesting that a small proportion of people living in Seattle were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – by around late March/early April 2020.

9 Dec 2020

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Researchers from the United States and The Netherlands have conducted a pre-clinical study supporting the initiation of a Phase 3 trial to test a two-dose regimen of the Janssen Ad26.COV2.S vaccine candidate among adult and elderly individuals.

19 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020

Optimizing SARS-COV-2 inactivation for COVID-19 research at lower biosafety levels

Researchers at Montana State University have validated and compared two methods for inactivating the causative agent of coronavirus disease 2019 (COVID-19) that would enable the virus to be studied at a lower biosafety level (BSL) than the one currently required.

18 Nov 2020

SARS-CoV-2 was circulating in Italy before China recognized its existence

This study, published in the Tumori Journal, sheds light on the possibility that the virus had been spreading in Italy well before the outbreak was officially reported in Wuhan, China.

17 Nov 2020

Males may have higher but more transient SARS-CoV-2 immunity than females post-infection

Adding another piece to the puzzle that is coronavirus disease 2019 (COVID-19) serology, a new study published on the preprint server medRxiv* in November 2020 suggests that males have stronger but more transient anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protective immunity than females.

17 Nov 2020

Research tracks humoral immunity response over eight months post COVID-19 infection

Researchers from Chongqing Medical University have tried to answer one of the burning questions regarding the longevity of immune response to coronavirus disease 2019 (COVID-19): How long does immunity last after infection? Their study looked at the lasting effects and continued immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over eight months after recovery from the infection.

11 Nov 2020

Lateral flow test enables faster, accurate diagnosis of periprosthetic joint infection

The recently FDA-authorized alpha-defensin lateral flow test is a highly accurate, ten-minute test for diagnosis of periprosthetic joint infection (PJI) - a serious and costly complication of total joint replacement, reports a study in The Journal of Bone & Joint Surgery.

9 Nov 2020

Study shows SARS-CoV-2 infection four times more likely through household transmission than community

A group of researchers from across the United States working in collaboration with their Swiss counterparts have conducted an extensive population-based serological survey to understand the transmission dynamics of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) – the novel agent that causes coronavirus disease 2019 (COVID-19).

8 Nov 2020

Cats shed SARS-CoV-2 RNA for a shorter duration compared to humans, study finds

Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19), there have been numerous reports of pets becoming infected. Both dogs and cats have been observed to exhibit symptoms of infection.

8 Nov 2020

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

“Our observations suggest that the presence of these autoantibodies may predispose SLE patients to infection with SARS-CoV-2 with a more severe presentation and represent an additional risk factor in this patient population,” write Sarthak Gupta and colleagues from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

5 Nov 2020

Majority of people infected with mild-to-moderate COVID 19 mount robust antibody response

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

29 Oct 2020

Seropositivity to SARS-CoV-2 among asymptomatic blood donors in New York

New York was the hardest-hit U.S. state during the peak of the outbreak in the country. Now, a team of researchers from the New York Blood Center and Serimmune, an immune intelligence company, aimed to determine the prevalence of seropositive people for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, among healthy blood donors.

23 Oct 2020